Bioverativ will be the name for the standalone hemophilia-focused company Biogen Inc. plans to spin out in early 2017. The company said Aug. 9 that the business separation remains on track and that an initial Form 10 registration statement will be filed with the Securities & Exchange Commission later this week.
Biogen announced plans to spin off its hemophilia franchise into a new company focused on blood disorders in May, though...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


